Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ExOlin Safety in Poorly Controlled Type 1 Diabetes
NCT05221359Recruiting
- Sponsor
- Defymed
- Start
- May 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Defymed. Primary endpoints: Percentage of patients with at least one relevant adverse event related to ExOlin at Week 36 and Percentage of patients with at least one relevant adverse event related to ExOlin (Extension) at Week 168. Started May 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05221359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221359.